Skip to main content

Table 4 Effect of treatment, patient and study variables on outcome

From: Albumin treatment regimen for type 1 hepatorenal syndrome: a dose–response meta-analysis

Variablea HRS Reversal Survival
Treatment Groups Odds Ratio (CI) p Groups Hazard Ratio (CI) p
Albumin dose (g) 23 1.15 (0.97-1.37) 0.10 15 1.15 (1.02-1.31) 0.023
Vasoconstrictor dose (mg) 23 0.86 (0.61-1.20) 0.38 15 1.28 (0.91-1.79) 0.16
Vasoconstrictor type 23 0.90 (0.51-1.57) 0.70 15 0.89 (0.49-1.59) 0.69
Treatment duration (d) 23 1.15 (0.46-2.89) 0.76 15 1.63 (0.84-3.13) 0.15
Patient       
Age (y) 21 0.99 (0.39-2.51) 0.99 15 1.37 (0.78-2.42) 0.28
Serum creatinine (mg/dL) 21 0.56 (0.31-1.01) 0.054 15 0.93 (0.52-1.65) 0.79
Serum bilirubin (mg/dL) 19 0.76 (0.37-1.57) 0.46 12 1.13 (0.65-1.94) 0.67
Serum albumin (g/dL) 20 1.11 (0.41-2.99) 0.83 13 1.58 (0.80-3.12) 0.19
MAP (mm Hg) 21 1.02 (0.41-2.55) 0.97 14 1.24 (0.71-2.15) 0.45
Study       
Design       
 Prospective 11 1.24 (0.36-4.29) 0.74 7 1.05 (0.55-1.99) 0.88
 Randomized 21 1.25 (0.56-2.84) 0.59 13 0.85 (0.44-1.64) 0.62
Number of patients 23 0.68 (0.45-1.04) 0.07 15 0.95 (0.68-1.33) 0.75
Year reported 23 1.38 (0.56-3.40) 0.48 15 0.84 (0.44-1.59) 0.58
  1. aAlbumin dose was analyzed per 100 g increment in cumulative dose. To allow comparisons between doses of different vasoconstrictors on a common scale, cumulative doses of each vasoconstrictor were standardized, with the values for midodrine and octreotide averaged. In the analysis of vasoconstrictor type, terlipressin was compared with other vasoconstrictors. To normalize data distributions, treatment duration and number of patients were log transformed. Patient variables were stratified by values above cutoffs equaling the pooled midpoint between the means of responders and nonresponders among the included studies as compared with lower values. The cutoffs were 53 y for age, 3.1 mg/dL for serum creatinine, 8.3 mg/dL for serum bilirubin, 2.8 g/dL for serum albumin, and 76 mm Hg for MAP. Prospective studies were compared with retrospective studies as the reference category, randomized studies with nonrandomized studies, and studies reported after 2005 with those before. Available data for HRS reversal were from 23 patient groups with 525 total patients and for time of survival from 15 patient groups with 377 total patients.
  2. Abbreviations: HRS, hepatorenal syndrome; MAP, mean arterial pressure.